Ni@TiO2 nanoribbon array electrode for high-efficiency non-enzymatic glucose biosensing.

The exploration of noble metal-free nanoarrays as high-activity catalytic electrodes for glucose biosensing holds great significance. Herein, we propose a Ni nanoparticle-decorated TiO2 nanoribbon array on a titanium plate (Ni@TiO2/TP) as an effective non-enzymatic glucose biosensing electrode. The as-prepared Ni@TiO2/TP electrode demonstrates rapid glucose response, a wide linear response range (1 µM to 1 mM), a low detection limit (0.08 µM, S/N = 3), and high sensitivity (10 060 and 3940 µA mM-1 cm-2), with good mechanical flexibility and stability. Moreover, it proves efficient in glucose biosensing in real human blood serum and cell culture fluid. Thus, it is highly promising for practical applications.

Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment.

Lung cancer (LC) is one of the most common cancer worldwide. Tumor-associated macrophages (TAMs) are important component of the tumor microenvironment (TME) and are closely related to the stages of tumor occurrence, development, and metastasis. Macrophages are plastic and can differentiate into different phenotypes and functions under the influence of different signaling pathways in TME. The classically activated (M1-like) and alternatively activated (M2-like) represent the two polarization states of macrophages. M1 macrophages exhibit anti-tumor functions, while M2 macrophages are considered to support tumor cell survival and metastasis. Macrophage polarization involves complex signaling pathways, and blocking or regulating these signaling pathways to enhance macrophages' anti-tumor effects has become a research hotspot in recent years. At the same time, there have been new discoveries regarding the modulation of TAMs towards an anti-tumor phenotype by synthetic and natural drug components. Nanotechnology can better achieve combination therapy and targeted delivery of drugs, maximizing the efficacy of the drugs while minimizing side effects. Up to now, nanomedicines targeting the delivery of various active substances for reprogramming TAMs have made significant progress. In this review, we primarily provided a comprehensive overview of the signaling crosstalk between TAMs and various cells in the LC microenvironment. Additionally, the latest advancements in novel drugs and nano-based drug delivery systems (NDDSs) that target macrophages were also reviewed. Finally, we discussed the prospects of macrophages as therapeutic targets and the barriers to clinical translation.

Ag@TiO2 nanoribbon array: a high-performance sensor for electrochemical non-enzymatic glucose detection in beverage sample.

Developing an accurate, cost-effective, reliable, and stable glucose detection sensor for the food industry poses a significant yet challenging endeavor. Herein, we present a silver nanoparticle-decorated titanium dioxide nanoribbon array on titanium plate (Ag@TiO2/TP) as an efficient electrode for non-enzymatic glucose detection in alkaline environments. Electrochemical evaluations of the Ag@TiO2/TP electrode reveal a broad linear response range (0.001 mM - 4 mM), high sensitivity (19,106 and 4264 µA mM-1 cm-2), rapid response time (6 s), and a notably low detection limit (0.18 µM, S/N = 3). Moreover, its efficacy in measuring glucose in beverage samples shows its practical applicability. The impressive performance and structural benefits of the Ag@TiO2/TP electrode highlight its potential in advancing electrochemical sensors for small molecule detection.

The role of dendritic cells in cancer immunity and therapeutic strategies.

Dendritic cells (DCs) are asserted as the most potent antigen-presenting cells (APCs) that orchestrate both innate and adaptive immunity, being extremely effective in the induction of robust anti-cancer T cell responses. Hence, the modulation of DCs function represents an attractive target for improving cancer immunotherapy efficacy. A better understanding of the immunobiology of DCs, the interaction among DCs, immune effector cells and tumor cells in tumor microenvironment (TME) and the latest advances in biomedical engineering technology would be required for the design of optimal DC-based immunotherapy. In this review, we focus on elaborating the immunobiology of DCs in healthy and cancer environments, the recent advances in the development of enhancing endogenous DCs immunocompetence via immunomodulators as well as DC-based vaccines. The rapidly developing field of applying nanotechnology to improve DC-based immunotherapy is also highlighted.